XY
Publicaties op Oncologisch.com
Camrelizumab plus rivoceranib versus sorafenib as eerstelijns therapy for unresectable hepatocellular carcinoma (CARE...
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously tr...
Surufatinib in gevorderd neuroendocrine tumours: Final totale overleving from two randomised, double-blind, placebo-c...
Toripalimab plus chemotherapie bij recidief NPC: JUPITER-02 definitief
Surufatinib bij pancreatische NET: SANET-p fase III
Surufatinib bij extrapancreatische NET: SANET-ep fase III